Combination therapy for airflow limitation in COPD

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Ghanei, Mostafa ^a   Nezhad, Leila Hoseini ^a   Harandi, Ali Amini ^b   Alaeddini, Farshid ^a   Shohrati, Majid ^a   Aslani, Jafar ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

COPD; Corticosteroids; Macrolide; reversibility; Theophylline

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; FAMOTIDINE; METOCLOPRAMIDE; OMEPRAZOLE; THEOPHYLLINE; BECLOMETASONE; IPRATROPIUM BROMIDE; PREDNISOLONE; SALMETEROL;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; SMOKING; DRUG EFFICACY; MAJOR CLINICAL STUDY; MORNING DOSAGE; OUTCOME ASSESSMENT; SMOKING CESSATION; SPIROMETRY; TREATMENT RESPONSE;

EID: 84872202188     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-6     Document Type: Article

References (36)

1. Interpreting COPD prevalence estimamtes: what is the true burden of disease? Halbert RJ, Isonaka S, George D, Iqbal A, Chest 2003 123 1684 1692 10.1378/chest.123.5.1684 12740290 (Pubitemid 36549792)
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee Committee GOLD Scientific, Am J Respir Crit Care 2001 163 1256 1276 (Pubitemid 32378468)
3. The global burden and impact of chronic obstructive pulmonary disease worldwide. Gulsvik A, Monaldi Arch Chest Dis 2001 56 261 264 11665507 (Pubitemid 32951968)
4. Chest X-ray and computed tomography in the evaluation of pulmonary emphysema. Irion KL, Hochhegger B, Marchiori E, Porto Nda S, Baldisserotto Sde V, Santana PR, J Bras Pneumol 2007 33 720 732 10.1590/S1806-37132007000600017 18200374
5. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Am J Respir Crit Care Med 2001 163 1256 1276 11316667 (Pubitemid 32378468)
6. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Barnes PJ, Shapiro SD, Pauwels RA, Eur Respir J 2003 22 672 688 10.1183/09031936.03.00040703 14582923 (Pubitemid 37258549)
7. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with a1-antitrypsin deficiency (PiZ). Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA, Am J Respir Crit Care Med 1999 160 1968 1975 10588615 (Pubitemid 30004705)
8. Infectious etiology of acute exacerbations of chronic bronchitis. Sethi S, Chest 2000 117 380S 385S 10.1378/chest.117.5-suppl-2.380S 10843981 (Pubitemid 30314471)
9. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE, Am J Respir Crit Care Med 2001 163 349 355 11179105 (Pubitemid 32158511)
10. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA, Eur Respir J 2001 17 1112 1119 10.1183/09031936.01.99114901 11491152 (Pubitemid 32717466)
11. Exacerbations. Etiology and pathophysiologic mechanisms. Wedzicha JA, Chest 2002 121 136S 141S 10.1378/chest.121.5-suppl.136S 12010842
12. Inflammation and infection in exacerbations of chronic obstructive pulmonary disease. Pietila MP, Thomas CF, Sem Resp Inf 2003 18 9 16 10.1053/srin.2003.50007 (Pubitemid 36373411)
13. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I, Stockley RA, Thorax 2003 58 680 685 10.1136/thorax.58.8.680 12885984 (Pubitemid 36976277)
14. Matrix metalloproteinases in asthma and COPD. Demedts IK, Brusselle GG, Bracke KR, Vermaelen KY, Pauwels RA, Curr Opin Pharmacol 2005 5 257 263 10.1016/j.coph.2004.12.005 15907912 (Pubitemid 40674248)
15. Oxidative stress in chronic obstructive pulmonary disease. Repine JE, Bast A, Lankhorst I, Am J Respir Crit Care Med 1997 156 341 357 9279209 (Pubitemid 27351964)
16. Oxidative stress and lung inflammation in airways disease. Macnee W, Eur J Pharmacol 2001 429 195 207 10.1016/S0014-2999(01)01320-6 11698041 (Pubitemid 33043996)
17. Dietary antioxidant vitamin intake and lung function in the general population. Britton JR, Pavord ID, Richards KA, Knox AJ, Wisniewski AF, Lewis SA, Tattersfield AE, Weiss ST, Am J Respir Crit Care Med 1995 151 1383 1387 7735589
18. Epidemiologic evidence linking antioxidant vitamins to pulmonary function and airway obstruction. Schunemann HJ, Freudenheim JL, Grant BJ, Epidemiol Rev 2001 23 248 267 10.1093/oxfordjournals.epirev.a000805 12192736 (Pubitemid 34074112)
19. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Reza Khajavi M, Reza Rouini M, Moradi M, Mohammadirad A, Abdollahi M, Hum Exp Toxicol 2007 26 697 703 10.1177/0960327107083452 17984140 (Pubitemid 350157338)
20. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ, Am J Respir Crit Care Med 1997 155 542 548 9032192 (Pubitemid 27085799)
21. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Culpitt SV, Nightingale JA, Barnes PJ, Am J Respir Crit Care Med 1999 160 1635 1639 10556133
22. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, Barnes PJ, Am J Respir Crit Care Med 2003 167 24 31 10.1164/rccm.200204-298OC 12406856 (Pubitemid 36015913)
23. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions inalveolarmacrophages. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM, FASEBJ 2001 15 1100 1102
24. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1b-induced histone H4 acetylation on lysines 8 and 12. Ito K, Barnes PJ, Adcock IM, Mol Cell Biol 2000 20 6891 6903 10.1128/MCB.20.18.6891-6903.2000 10958685
25. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ, Proc Natl Acad Sci USA 2002 99 8921 8926 10.1073/pnas.132556899 12070353 (Pubitemid 34693659)
26. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-κB activation. Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, Takizawa H, Antimicrob Agent Chemother 2004 48 1581 1585 10.1128/AAC.48.5.1581-1585.2004 (Pubitemid 38544362)
27. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, Tokue Y, Watanabe A, Nukiwa T, J Antimicrob Chemother 2002 49 745 755 10.1093/jac/dkf008 12003967 (Pubitemid 34537634)
28. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH, J Clin Invest 1990 85 682 689 10.1172/JCI114492 2107207 (Pubitemid 20087469)
29. Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules. Takeyama K, Agusti C, Ueki I, Lausier J, Cardell LO, Nadel JA, Am J Physiol 1998 275 294 L302 9700090
30. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Gorrini M, Lupi A, Viglio S, Pamparana F, Cetta G, Iadarola P, Powers JC, Luisetti M, Am J Respir Cell Mol Biol 2001 25 492 499 11694455 (Pubitemid 33037682)
31. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Goswami SK, Kivity S, Marom Z, Am Rev Respir Dis 1990 141 72 78 2404441 (Pubitemid 20023385)
32. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Tamaoki J, Takeyama K, Tagaya E, Konno K, Antimicrob Agent Chemother 1995 39 1688 1690 10.1128/AAC.39.8.1688
33. The effects of macrolides on the expression of bacterial virulence mechanisms. Shryock TR, Mortensen JE, Baumholtz M, J Antimicrob Chemother 1998 41 505 512 10.1093/jac/41.5.505 9630404 (Pubitemid 28230304)
34. New perspectives on macrolide antibiotics. Pechere JC, Int J Anti-microb Agents 2001 18 93 S97
35. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Wozniak DJ, Keyser R, Chest 2004 125 62S 69S 10.1378/chest.125.2-suppl.62S 14872002 (Pubitemid 38200962)
36. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. Mainie I, Tutuian R, Castell DO, J Clin Gastroenterol 2008 42 676 679 10.1097/MCG.0b013e31814a4e5c 18496394